Skip to content

Intense Pulsed Light Combined with Systane iLux™ versus Mechanical Meibomian Gland Expression for Meibomian Gland Dysfunction-Related Dry Eye

Intense Pulsed Light Combined with Systane iLux™ versus Mechanical Meibomian Gland Expression for Meibomian Gland Dysfunction-Related Dry Eye

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116201
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

ILUX group:Both groups received standardized eyelid warming and IPL therapy prior to their respective adjunctive treatments (Systane iLux System).
Control group:Both groups received standardized eyelid warming and IPL therapy prior to their respective adjunctive treatments (MMGX).

Sponsors

Tianjin medical university eye hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ubjects aged between 18 and 70 years are eligible for inclusion if they meet the following key criteria: participants must simultaneously satisfy the diagnostic criteria for dry eye disease (DED) and meibomian gland dysfunction (MGD). Diagnostic criteria for DED used in this study were based on the Chinese Expert Consensus on Dry Eye Disease [9,10]: 1 Visual Surface Disease Index (OSDI) >= 13; fluorescein tear film break-up time (FBUT) = 13; and 5 s = 5 spots. Diagnostic criteria for MGD used in this study were based on the International Workshop on Meibomian Gland Dysfunction standards [11]: abnormal meibomian gland orifices (e.g., blockage, narrowing, or posterior displacement); altered secretion quality (e.g., cloudy, granular, or inspissated/toothpaste-like material); or meibomian gland dropout (confirmed by meibomian gland imaging).

Exclusion criteria

Exclusion criteria: history of ocular surgery and laser treatment within 3 months; use of topical eye drops for the within 3 months; use of systemic medications affecting DED or contact lens wear within 3 months; abnormalities in the cornea, conjunctiva or eyelid; any systemic diseases associated with MGD or DED.

Design outcomes

Primary

MeasureTime frame
FBUT;

Secondary

MeasureTime frame
LLT;Meibomian gland evaluation;

Countries

China

Contacts

Public ContactChen Zhang

Tianjin medical university eye hospital

zhaosz1997@sina.com+86 86428710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026